top of page
  • Writer's pictureagbiopro

A 1.2 Bilion Gene Therapy Deal

Updated: Apr 22, 2019

Less than a month after Thermo Fisher unveiled a $1.7 billion deal to swallow Brammer Bio — a company that does contract viral vector manufacturing for cell and gene therapy developers — Catalent is planning to fork over $1.2 billion for private-equity backed Paragon Bioservices.

7 views0 comments


bottom of page